Kris Elverum joined Rubius as Senior Vice President of Business Development and Strategy in July 2019, to develop the Company’s corporate strategy and create and execute new business development opportunities. He brings to Rubius more than 15 years in the pharmaceutical and biotechnology industry with expertise in business development, commercial, and corporate strategy. Kris joins Rubius from Turnstone Biologics, where he executed a collaboration with AbbVie, representing the largest oncolytic virus strategic partnership, and in-licensed multiple technologies. Prior to Turnstone, Kris was with SQZ Biotech and was integral to a research partnership with Roche. Earlier in his career, Kris worked at Novartis, where he held roles in CAR-T cell launch planning, neuroscience sales and marketing, and Sandoz global strategy and market intelligence. Kris began his career at McKinsey & Co., and authored a review in Nature on commercializing cell and gene therapies.
Kris holds an MBA and B.S. from the University of Minnesota’s Carlson School of Management.